ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Dow Jones Industrial Average's 3.4% fall on Monday, Feb. 23, took it down to 7,114.78—half the peak level it achieved on Oct. 9, 2007. Chemical stocks followed suit. Standard & Poor's chemical stock index, which includes firms ranging from Dow Chemical to Sigma-Aldrich, dipped to 162.81—a 49% drop from the same day in October 2007. However, S&P's health care index, which includes major pharmaceutical, biotech, and medical device companies, experienced a less precipitous drop over the 16-month period, falling 30% to 292.88. Analysts agree that the softer fall for drug stocks reflects the industry's overall more secure position compared with the chemical industry, which serves basic industrial markets. "Despite their problems, the drug companies have plenty of cash," says Michael A. Martorelli, an analyst at investment banking and capital advisory firm Fairmount Partners. "They are among the highest dividend payers around right now. I don't think anybody doubts the survivability of the big pharma or even midsized pharma companies."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter